リラグルチド (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "リラグルチド" in Japanese language version.

refsWebsite

Global rank Japanese rank

10doi.org

2^nd place

6^th place

7nih.gov

4^th place

24^th place

2jds.or.jp

low place

2nejm.org

2,374^th place

2,486^th place

2reuters.com

49^th place

67^th place

2fda.gov

447^th place

1,043^rd place

1drugs.com

399^th place

1,603^rd place

1crcpress.com

low place

1diabetesjournals.org

low place

1clinicaltrials.gov

5,225^th place

low place

1wikipedia.org

low place

1novonordisk.com

low place

1pmda.go.jp

6,690^th place

394^th place

1drugdevelopment-technology.com

low place

1dm-net.co.jp

low place

1sciencedirect.com

149^th place

558^th place

clinicaltrials.gov

“Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes”. ClinicalTrials.gov（英語版） (13 November 2014). 17 January 2015閲覧。

crcpress.com

Goldstein, Barry J.; Mueller-Wieland, Dirk (14 November 2007). Type 2 Diabetes: Principles and Practice (2nd ed.). CRC Press. ISBN 978-0-8493-7958-1 17 January 2015閲覧。

diabetesjournals.org

care.diabetesjournals.org

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. (2009). “Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.”. Diabetes Care 32 (1): 84-90. doi:10.2337/dc08-1355. PMC 2606836. PMID 18931095.

dm-net.co.jp

糖尿病ネットワーク (2010年1月21日). “国内初のGLP-1受容体作動薬「ビクトーザ」の承認取得”. 2016年4月1日閲覧。

doi.org

Beglinger C, Degen L (2007). “Gastrointestinal satiety signals in humans—physiologic roles for GLP-1 and PYY ?”. Physiol. Behav. 89 (4): 460–4. doi:10.1016/j.physbeh.2006.05.048. PMID 16828127.
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. (2009). “Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.”. Diabetes Care 32 (1): 84-90. doi:10.2337/dc08-1355. PMC 2606836. PMID 18931095.
山内一郎、松本義弘, 満田佳名子, 保田紀子, 吉田有希子, 中野厚生, 田中早津紀, 前田康司, 新谷光世, 西村治男「ステロイド投与中の血糖コントロールにおけるリラグルチドの有効性」『糖尿病』第57巻第2号、2014年3月11日、102-7頁、doi:10.11213/tonyobyo.57.102、2016年4月1日閲覧。
Shyangdan D, Cummins E, Royle P, Waugh N (May 2011). “Liraglutide for the treatment of type 2 diabetes”. Health Technol Assess 15 Suppl 1: 77–86. doi:10.3310/hta15suppl1/09. PMID 21609656.
リラグルチドの有害事象による中止の危険因子の探索糖尿病 Vol.58 (2015) No.3 p.159-166
油井美智子ほか、リラグルチド投与開始後に味覚障害および角膜障害が出現した1例糖尿病 Vol.57 (2014) No.12 p.893-899
Parks M, Rosebraugh C (2010). “Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.”. N Engl J Med 362 (9): 774-7. doi:10.1056/NEJMp1001578. PMID 20164475.
Sonal Singh; Hsien-Yen Chang; Thomas M. Richards; Jonathan P. Weiner; Jeanne M. Clark; Jodi B. Segal (April 8, 2013). “Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus”. JAMA Internal Medicine 173: 534. doi:10.1001/jamainternmed.2013.2720.
“Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment — NEJM”. The New England Journal of Medicine 370: 794–7. (February 27, 2014). doi:10.1056/NEJMp1314078. PMID 24571751 January 17, 2015閲覧。.
McClean PL, Hölscher C (2014). “Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.”. Neuropharmacology 76 Pt A: 57-67. doi:10.1016/j.neuropharm.2013.08.005. PMID 23973293.

drugdevelopment-technology.com

http://www.drugdevelopment-technology.com/projects/liraglutide/ "Liraglutide - Next-Generation Antidiabetic Medication"

drugs.com

http://www.drugs.com/nda/liraglutide_080530.html May 2008

fda.gov

accessdata.fda.gov

“www.accessdata.fda.gov”. 2016年4月1日閲覧。

fda.gov

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2010/ucm198638.htm "FDA Approves New Treatment for Type 2 Diabetes" January 25, 2010

jds.or.jp

ビクトーザR皮下注に関する安全性情報ノボノルディスクファーマ株式会社 2010年10月（日本糖尿病学会）
インクレチン（GLP-1受容体作動薬とDPP-4阻害薬）の適正使用に関する委員からの報告日本糖尿病学会

nejm.org

nih.gov

pubmed.ncbi.nlm.nih.gov

Beglinger C, Degen L (2007). “Gastrointestinal satiety signals in humans—physiologic roles for GLP-1 and PYY ?”. Physiol. Behav. 89 (4): 460–4. doi:10.1016/j.physbeh.2006.05.048. PMID 16828127.
Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. (2009). “Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.”. Diabetes Care 32 (1): 84-90. doi:10.2337/dc08-1355. PMC 2606836. PMID 18931095.
Shyangdan D, Cummins E, Royle P, Waugh N (May 2011). “Liraglutide for the treatment of type 2 diabetes”. Health Technol Assess 15 Suppl 1: 77–86. doi:10.3310/hta15suppl1/09. PMID 21609656.
Parks M, Rosebraugh C (2010). “Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.”. N Engl J Med 362 (9): 774-7. doi:10.1056/NEJMp1001578. PMID 20164475.
“Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment — NEJM”. The New England Journal of Medicine 370: 794–7. (February 27, 2014). doi:10.1056/NEJMp1314078. PMID 24571751 January 17, 2015閲覧。.
McClean PL, Hölscher C (2014). “Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.”. Neuropharmacology 76 Pt A: 57-67. doi:10.1016/j.neuropharm.2013.08.005. PMID 23973293.

pmc.ncbi.nlm.nih.gov

Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. (2009). “Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.”. Diabetes Care 32 (1): 84-90. doi:10.2337/dc08-1355. PMC 2606836. PMID 18931095.

novonordisk.com

New phase 3a data demonstrate that 9 out of 10 adults with obesity lost weight with liraglutide 3 mg and clinical trial completers lost an average of 9.2% (PDF). ObesityWeek 2014. Boston: Novo Nordisk A/S. 4 November 2014. 2015年1月17日閲覧。

pmda.go.jp

info.pmda.go.jp

“ビクトーザ皮下注18mg 添付文書” (2014年8月). 2016年4月1日閲覧。

reuters.com

sciencedirect.com

McClean PL, Hölscher C (2014). “Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.”. Neuropharmacology 76 Pt A: 57-67. doi:10.1016/j.neuropharm.2013.08.005. PMID 23973293.

wikipedia.org

en.wikipedia.org

“Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes”. ClinicalTrials.gov（英語版） (13 November 2014). 17 January 2015閲覧。